|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
Netherlands Trial Register |
|
Last refreshed on:
|
28 April 2013 |
|
Main ID: |
NTR87 |
|
Date of registration:
|
06/05/2005 |
|
Primary sponsor: |
|
|
Public title:
|
Selenium supplementation in euthyroid patients with thyroid peroxidase antibodies.
|
|
Scientific title:
|
Selenium supplementation in euthyroid patients with thyroid peroxidase antibodies.
- N/A |
|
Date of first enrolment:
|
1/8/2005 |
|
Target sample size:
|
150 |
|
Recruitment status: |
complete |
|
URL:
|
http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=87 |
|
Study type:
|
intervention |
|
Study design:
|
Randomised: Yes; Masking: Double; Control: Placebo; Group: Parallel; Type: 2 or more arms, randomized
|
|
|
Countries of recruitment
|
|
The Netherlands
| | | | | | | |
|
Contacts
|
|
Name:
|
S.A.
Eskes |
|
Address:
|
Academic Medical Center (AMC),
Department of Endocrinology,
P.O. Box 22660, Meibergdreef 9
1100 DD
Amsterdam
The Netherlands |
|
Telephone:
|
+31 (0)20 5669111 |
|
Email:
|
S.A.Eskes@amc.uva.nl |
|
Affiliation:
|
|
|
|
Name:
|
W.M.
Wiersinga |
|
Address:
|
Academic Medical Center (AMC), Department of Endocrinology and Metabolism,
P.O. Box 22660, Meibergdreef 9
1105 AZ
Amsterdam
The Netherlands |
|
Telephone:
|
+31 (0)20 5669111 |
|
Email:
|
w.m.wiersinga@amc.uva.nl |
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Thyroid peroxidase antibodies >100 kU/l, TSH 0.4-4.0 mE/L, FT4 10-23 pmol/l, T3 1.30-2.70 nmol/L, female sex.
Exclusion criteria: Use of multivitamin tablets containing selenium in the month preceding inclusion, drug or alcohol abuse, no informed consent.
Age minimum:
Age maximum:
Gender:
|
|
Health Condition(s) or Problem(s) studied
|
Euthyroidism, Thyroid peroxidase antibodies
|
|
Intervention(s)
|
|
Selenium supplementation or placebo.
|
|
Primary Outcome(s)
|
|
Change of TPO-antibody concentration, difference in TSH level.
|
|
Secondary Outcome(s)
|
|
Development of subclinical or overt hypothyroidism and quality of life estimation.
|
|
Secondary ID(s)
|
|
04/072
|
|
ISRCTN26633557
|
|
Source(s) of Monetary Support
|
|
Academic Medical Center (AMC)
|
|